Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Testing a less frequent osimertinib schedule in EGFR lung cancer
Tests a longer gap between osimertinib doses in adults with EGFR-mutated lung cancer.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Amsterdam, Groningen, Leiden, Maastricht, Nijmegen, Rotterdam, and Utrecht, NetherlandsSee the 7 sitesAlso in 1 other country, 10 sites
- Trial code
- Registry title
- Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 283 people, planned
- Started
- 28 Oct 2025
- Expected to end
- 1 Oct 2031
- Type of study
- Interventional
- Record updated
- 27 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced EGFR-mutated lung cancer who have been taking osimertinib for at least three months and whose cancer has responded.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 19 deletion or exon 21 L858R mutation, not able to have treatment meant to remove all of the disease.
- Earlier treatment
- First-line osimertinib 80 mg once a day, with or without chemotherapy, for at least three months as standard care, with a response on scans.
- Biomarker or test result
- EGFR exon 19 deletion or exon 21 L858R mutation.
Main reasons for not taking part
- Known CNS (brain or spinal cord) metastases at the start
- Use of strong CYP3A4 inducers
- Treatment side effects for which the osimertinib dose should be reduced
- Pregnant, breastfeeding or actively trying to conceive
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥18 years
- Able to understand the written information and able to give informed consent
- Sufficient knowledge of the local language in order answer the questionnaires
- Locally advanced or metastatic NSCLC with an EGFR exon 19 deletions or exon 21 L858R muta-tions not eligible for curative intent therapy
- Treatment with first-line osimertinib 80 mg QD with or without chemotherapy for at least three months according to standard of care
- A response on radiologic assessment (response is defined as: - complete or partial response as defined by RECIST 1.1, assessed by the treating physi-cian. - a radiological response according to the treating physician that does not meet the crite-ria for partial response according to RECIST 1.1.)
Who cannot take part
- Patients with known CNS metastases at baseline
- Usage of strong CYP3A4 inducers as described in 9.1.2
- Treatment related toxicity for which a dose reduction of osimertinib is indicated
- Patients who are either pregnant, breastfeeding or actively trying to conceive
Where in Netherlands
Also in 1 other country, 10 sites
- Amsterdam UMCAmsterdam, NetherlandsTaking people
- University Medical Center GroningenGroningen, NetherlandsTaking people
- Leiden University Medical CenterLeiden, NetherlandsTaking people
- Maastricht University Medical CenterMaastricht, NetherlandsTaking people
- Radboud University Medical CenterNijmegen, NetherlandsTaking people
- Erasmus Medisch Centrum 1Rotterdam, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
About the trial
What the trial wants to find out
The assessment of the non-inferiority of an extended dosing interval of osimertinib compared to the standard dosage.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE
- Plain-language title
- Testing a less frequent osimertinib schedule in EGFR lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 March 2026